drugset / Trial / NCT05778097
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Phase 2
Not yet recruiting
103 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Xian-Janssen Pharmaceutical Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2026-08-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 240 mg | — |